148 related articles for article (PubMed ID: 19132193)
1. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
2. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
4. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
[TBL] [Abstract][Full Text] [Related]
7. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
8. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
[TBL] [Abstract][Full Text] [Related]
9. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
10. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
11. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
12. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients.
Merkel N; Gunther G; Schobess R
Acta Haematol; 2006; 115(3-4):230-6. PubMed ID: 16549901
[TBL] [Abstract][Full Text] [Related]
14. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
Hicks JK; Shelton CM; Sahni JK; Christensen ML
Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.
Kuhle S; Massicotte P; Dinyari M; Vegh P; Mitchell D; Marzinotto V; Chan A; Pieniaszek H; Mitchell LG
Thromb Haemost; 2005 Dec; 94(6):1164-71. PubMed ID: 16411388
[TBL] [Abstract][Full Text] [Related]
16. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
Ignjatovic V; Najid S; Newall F; Summerhayes R; Monagle P
Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates.
Goldsmith R; Chan AK; Paes BA; Bhatt MD;
J Perinatol; 2015 Oct; 35(10):852-4. PubMed ID: 26181722
[TBL] [Abstract][Full Text] [Related]
20. Higher Tinzaparin Dosing Is Needed to Achieve Target Anti-Xa Levels in Pediatric Cardiac Intensive Care Patients.
Roeleveld PP; van der Hoeven A; de Wilde RB; Eikenboom J; Smiers FJ; Bunker-Wiersma HE
Pediatr Crit Care Med; 2016 Mar; 17(3):203-9. PubMed ID: 26808621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
